Diuretic effects of fenoldopam in healthy cats

Journal of Veterinary Emergency and Critical Care

Volumn 16, Issue 2, 2006, Pages 96-103

  Simmons, Jeffery P ^a,b   Wohl, James S ^a   Schwartz, Dean D ^a   Edwards, Heather G ^a   Wright, James C ^a  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

DA 1; Dopamine receptor; Dopaminergic; Feline; Renal

Indexed keywords

ANIMALIA; FELIDAE;

EID: 33646892201     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2006.00176.x     Document Type: Article

References (59)

1. Antonipillai IBM, Lang D. Evidence that specific dopamine 1 receptor activation is involved in dopamine induced renin release. Hypertension 1989 13 : 463 468.
2. Hughes JMBT, Rose CE, Carey RM. Selective dopamine 1 receptor stimulation produces natriuresis by a direct tubular action. J Hypertens 1986 4 Suppl. : S106 S108.
3. Wohl J, Schwartz D, Flournoy W. Renal hemodynamics and diuretic effects of low-dose dopamine in the cat, In : Seventh International Veterinary Emergency and Critical Care Symposium. American College of Veterinary Emergency and Critical Care: Veterinary Emergency and Critical Care Society Orlando, FL, 2000, pp. 14 24.
4. Flournoy WS, Wohl JS, Albrecht-Schmitt TJ, et al. Pharmacologic identification of putative D1 dopamine receptors in feline kidneys. J Vet Pharmacol Ther 2003 26 4 : 283 290.
5. Jorkasky DK, Audet P, Shusterman N, et al. Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients. Am J Kidney Dis 1992 19 6 : 567 572.
6. Madyoon H, Croushore L, Weaver D, et al. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 2001 53 3 : 341 345.
7. Madyoon H, Croushore L. Use of fenoldopam for prevention of radiocontrast nephropathy in the cardiac catheterization laboratory : a case series. J Interv Cardiol 2001 14 2 : 179 185.
8. Tumlin JA, Wang A, Murray PT, et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion : a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002 143 5 : 894 903.
9. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999 27 9 : 1832 1837.
10. O'Connell DP, Ragsdale NV, Boyd DG, et al. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 1997 29 1 Pt 1 : 115 122.
11. Halpenny M, Markos F, Snow HM, et al. Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs. Crit Care Med 2001 29 4 : 855 860.
12. Dlewati A, Lokhandwala MF. Dose-response analysis of the effects of fenoldopam, a dopamine-1 receptor agonist, on renal function. Drug Develop Res 1991 22 : 59 68.
13. Halpenny M, Markos F, Snow HM, et al. The effects of fenoldopam on renal blood flow and tubular function during aortic cross-clamping in anaesthetized dogs. Eur J Anaesthesiol 2000 17 8 : 491 498.
14. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction : a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) clinical trials group. Lancet 2000 356 9248 : 2139 2143.
15. Wassermann K, Huss R, Kullmann R. Dopamine-induced diuresis in the cat without changes in renal hemodynamics. Naunyn Schmiedebergs Arch Pharmacol 1980 312 1 : 77 83.
16. Rose B. Meaning and application of Urine chemistries In:Rose B. ed. Clinical Physiology of Acid-Base and Electrolyte Disorders, 4th edn. New York : McGraw-Hill Book Co 1994, pp. 47 51, 380-382.
17. Clark KL, Robertson MJ, Drew GM. Do renal tubular dopamine receptors mediate dopamine-induced diuresis in the anesthetized cat? J Cardiovasc Pharmacol 1991 17 2 : 267 276.
18. Lokhandwala MF, Amenta F. Anatomical distribution and function of dopamine receptors in the kidney. FASEB J 1991 5 15 : 3023 3030.
19. Grider JS, Ott CE, Jackson BA. Dopamine D1 receptor-dependent inhibition of NaCl transport in the rat thick ascending limb : mechanism of action. Eur J Pharmacol 2003 473 2-3 : 185 190.
20. Murphy MB. Dopamine : a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 2000 14 Suppl. 1 : S47 S50.
21. Olsen NV. Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans. Dan Med Bull 1998 45 3 : 282 297.
22. Tumlin JA, Dunbar LM, Oparil S, et al. Fenoldopam, a dopamine agonist, for hypertensive emergency : a multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med 2000 7 6 : 653 662.
23. Panacek EA, Bednarczyk EM, Dunbar LM, et al. Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group. Acad Emerg Med 1995 2 11 : 959 965.
24. Weber RRMC, Ziemniak JA, Frederickson ED, et al. Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine 1 receptor agonist, in hypertensive patients. Br J Clin Pharmacol 1988 25 : 17 21.
25. Ichai C, Passeron C, Carles M, et al. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients : a single-blind, prospective, controlled study. Crit Care Med 2000 28 5 : 1329 1335.
26. Asif A, Preston RA, Roth D. Radiocontrast-induced nephropathy. Am J Ther 2003 10 2 : 137 147.
27. Biancofiore G, Della Rocca G, Bindi L, et al. Use of fenoldopam to control renal dysfunction early after liver transplantation. Liver Transpl 2004 10 8 : 986 992.
28. Chamsuddin AA, Kowalik KJ, Bjarnason H, et al. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. Am J Roentgenol 2002 179 3 : 591 596.
29. Madyoon H. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. Rev Cardiovasc Med 2001 2 Suppl. 1 : S26 S30.
30. Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Rev Cardiovasc Med 2001 2 Suppl. 1 : S4 S8.
31. Morelli A, Rocco M, Conti G, et al. Monitoring renal oxygen supply in critically-ill patients using urinary oxygen tension. Anesth Analg 2003 97 6 : 1764 1768.
32. Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg 2004 78 4 : 1332 1337 discussion 1337-1338.
33. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy : a randomized controlled trial. J Am Med Assoc 2003 290 17 : 2284 2291.
34. Umrani DN, Goyal RK. Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats. Clin Exp Hypertens 2002 24 3 : 207 219.
35. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998 31 5 : 743 755.
36. Mathur VS. The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Rev Cardiovasc Med 2003 4 Suppl. 1 : S35 S40.
37. Murphy MB, Murray C, Shorten GD. Fenoldopam : a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Eng J Med 2001 345 21 : 1548 1557.
38. Ng SS, Pang CC. In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist. Br J Pharmacol 2000 129 5 : 853 858.
39. Guzman JA, Rosado AE, Kruse JA. Dopamine-1 receptor stimulation impairs intestinal oxygen utilization during critical hypoperfusion. Am J Physiol Heart Circ Physiol 2003 284 2 : H668 675.
40. Guzman JA, Rosado AE, Kruse JA. Dopamine-1 receptor stimulation attenuates the vasoconstrictive response to gut ischemia. J Appl Physiol 2001 91 2 : 596 602.
41. Halpenny M, Lakshmi S, O'Donnell A, et al. Fenoldopam : renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001 56 10 : 953 960.
42. Morelli A, Rocco M, Conti G, et al. Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock. Anesthesiology 2004 101 3 : 576 582.
43. Napolitano LM. Optimization of intestinal mucosal oxygenation in shock : a role for medical therapy? Crit Care Med 2004 32 1 : 301 302.
44. Schwarte LA, Picker O, Schindler AW, et al. Fenoldopam - but not dopamine - selectively increases gastric mucosal oxygenation in dogs. Crit Care Med 2003 31 7 : 1999 2005.
45. Azzam ZS, Saldias FJ, Comellas A, et al. Catecholamines increase lung edema clearance in rats with increased left atrial pressure. J Appl Physiol 2001 90 3 : 1088 1094.
46. Miller Q, Peyton BD, Cohn EJ, et al. The effects of intraoperative fenoldopam on renal blood flow and tubular function following suprarenal aortic cross-clamping. Ann Vasc Surg 2003 17 6 : 656 662.
47. Caimmi PP, Pagani L, Micalizzi E, et al. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2003 17 4 : 491 494.
48. Chu VL, Cheng JW. Fenoldopam in the prevention of contrast media-induced acute renal failure. Ann Pharmacother 2001 35 10 : 1278 1282.
49. Marik P. Low-dose dopamine : a systemic review. Intensive Care Med 2002 28 : 877 883.
50. Romano G, Ferraccioli G. Usefulness of dopamine treatment in non-oliguric renal failure. Lancet 2001 357 9260 : 960.
51. Delzell JE Jr.. Is low-dose dopamine effective in preventing renal dysfunction in patients in the intensive care unit (ICU)? J Fam Pract 2001 50 4 : 369.
52. Kellum JA, M Decker J. Use of dopamine in acute renal failure : a meta-analysis. Crit Care Med 2001 29 8 : 1526 1531.
53. O'Hara JF Jr.. Low-dose "renal" dopamine. Anesthesiol Clin North Am 2000 18 4 : 835 851, ix.
54. Chertow GM, Sayegh MH, Allgren RL, et al. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin anaritide acute renal failure study group. Am J Med 1996 101 1 : 49 53.
55. Segal JM, Phang PT, Walley KR. Low-dose dopamine hastens onset of gut ischemia in a porcine model of hemorrhagic shock. J Appl Physiol 1992 73 3 : 1159 1164.
56. Dhasmana KM, Villalon CM, Zhu YN, et al. The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res 1993 27 4 : 335 347.
57. Juste RN, Moran L, Hooper J, et al. Dopamine clearance in critically ill patients. Intensive Care Med 1998 24 11 : 1217 1220.
58. Kini AA, Sharma SK. Managing the high-risk patient : experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001 2 Suppl 1 : S19 S25.
59. Zimmerman-Pope N, Waldron DR, Barber DL, et al. Effect of fenoldopam on renal function after nephrotomy in normal dogs. Vet Surg 2003 32 6 : 566 573.